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The factors responsible for the appearance of autoantibodies after viral infec-
tions have not been well understood . Infectious mononucleosis (IM)' is charac-
terized by a particularly high incidence of autoantibodies, including the hetero-
phile antibody, rheumatoid factor, and among those assayed by immunofluores-
cence, antibodies to the cytoskeleton (1-7). 70-90% of acute IM patients have
high titers ofIgM autoantibodies to the vimentin class of intermediate filaments
(4) . 30-60% have IgM antikeratin antibodies (5) . Individuals who have had
Epstein-Barr virus (EBV) infections in the distant past, or individuals with no
previous EBV infection, have none or only very low titers of these antibodies.
Autoantibodies are also produced during other viral infections (6, 8).
A number of hypotheses have been generated to account forsuch autoantibody
production . The first is that the antibodies are produced in response to normally
sequestered cellular proteins that are released during cell lysisanddeath, thereby
allowing them to be taken up by macrophages and presented as antigen to the
immune system . A second mechanism proposed is that antibodies made to
microbial antigens can crossreact with normal cellular proteins . The best known
example of this mechanism is the production of antibodies to the myocardium
during streptococcal infection (9, 10) . This mechanism has recently been rein-
vestigated with respect to viral or mycoplasmal antigens (11-16) and popularized
under the term molecular mimicry, although perhaps the more neutral term
epitope homology would be better. A third mechanism particularly pertinent to
infection by EBV is that the virus acts as a polyclonal B cell activator . The virus
randomly infects B cells and induces the secretion of whatever antibodies the B
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Peptide sequence of the EBNA-1 molecule (one-letter amino acid code). The
glycine-alanine repeat is shaded . Peptide F12 begins at residue 1 and peptide F13 at residue
54, both entirely outside the glycine-alanine repeat . P27 begins at residue 83 and spans the
NH 3-terminal endof the repeat . P60 begins at residue 314 and ends at theR terminating the
repeat. F14, F15, F16, and P62 occur four, three, one, and three times, respectively, entirely
within the repeat .
cell is preprogrammed to make, antibodies generally unrelated to the virus itself.
Some of these antibodies may include autoantibodies (17-20) .
Among the many virally encoded proteins generated during EBV infection,
the Epstein-Barr nuclear antigen (EBNA-1) has been of particular interest . It is
generated in latently as well as productively infected B cells, and antibodies to it
arise after infection and persist for the rest of the individual's life (21, 22) . The
EBNA-1 molecule plays a critical role in maintenance of viral DNA in the
infected cell (23) . In addition, patients with certain autoimmune diseases have
higher levels of antibodies to EBNA-1 (24, 25) and to synthetic peptides derived
from EBNA-1 (26) than a normal control group .
The EBNA-1 protein has a very unusual structure in which about one-third of
the protein consists ofa repeated sequence that contains only glycine or alanine
(27-29) (Fig . 1) . DNA sequences homologous to the viral region that encodes
the glycine-alanine portion are present on all human chromosomes except theY
(30) . These sequences are transcribed into a number of RNA molecules (31-33)
and some may be translated into protein (33, 34).
We have examined the IgM antibodies produced during acute IM, and have
found antibodies that recognize at least 10 cellular proteins . Most of the auto-
antibodies reactive with these proteins are highly crossreactive with each other
andare inhibited by synthetic peptides containing portions of the glycine-alanine
repeating area of the virally encoded EBNA-I protein . Thus the IgM autoanti-
bodies produced during IM appear to be made to a specific region of a viral
protein, and crossreact with homologous epitopes on host proteins . The IgG
anti-EBNA-1 antibodies that arise during late convalescence fail to exhibit the
crossreactive features of the IgM anti-EBNA-1 .1028
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Cell lines were obtained from the American Type Culture Collection (Rockville,
MD), except for the line DHL-9 (35, 36). They were grown in RPMI 1640 supplemented
with 10% FCS and 1 % L-glutamine. The cells were harvested in late exponential growth
and washed four times with PBS (10 mM sodium phosphate, 150 mM NaCI, pH 6.8). 100
Al of diluted electrophoresis mix (2% SDS, 2% 2-ME, 0 .004% bromphenol blue, 40 mM
Tris-HC1, pH 6.8, and 15% glycerol) and 2 Al of PMSF (5 mM PMSF dissolved in ethanol)
were added for each 106 cell and the solution was heated to 100°C for 5 min and stored
frozen . Protein concentration was determined by the Peterson modification (37-39) of
the Lowry method (40). This procedure results in a protein concentration of 1-2 mg/ml.
Cell Fractionation.
￿
Cells were lysed and nuclei were pelleted as described (41). The
nuclear pellet was resuspended in DEM, boiled, and stored at -20°C. This we called the
nuclear fraction . The supernatant from the above step was spun at 145,000 g for 1 h
(sufficient to pellet all particles having a sedimentation coefficient >120 S). The super-
natant from this spin was designated the cytoplasmic fraction. It was mixed with one-fifth
the volume of 5X DEM, boiled, and stored frozen until needed. The pellet was resus-
pended in DEM and called the particulate fraction. It contains cell organelles as well as
membranes. Because of the way the supernatant was removed, the membrane fraction is
slightly contaminated with the cytoplasmic fraction.
Sera. Serum samples from IM patients were collected from students when they
presented with clinical symptoms, and again 1 mo later. The initial serum samples were
all heterophile-positive and all had elevated IgM and low or no IgG anti-peptide P62
antibody levels (42). 30-50 ml of blood was collected directly in 50 ml of RPMI-1640
tissue culture media, and this was then loaded onto a Ficoll density gradient to isolate
cells. After centrifugation the serum supernatant was removed and frozen. Thus, the
serum samples are diluted 1 :2-1 :2 .5 when frozen . All dilutions referred to in this paper
refer to dilutions from this frozen sample.
Peptides and Proteins.
￿
The peptides used in this study were synthesized by the solid-
phase method of Merrifield (43), modified as described (44). The sequences of the peptide
are: F12, IMSDEGPGTGPGNGLGE; F13, PGAPGGSGSGP; F14, GGAGGAGGA-
GAGGGAG; F15, GAGGAGAGGGAGGAGG; F16, GGAGAGGAGAGGAGAGGA-
GAG; P27, KGTMGGTGAGAGAGGAGAG; P60, GGGAGAGGAGAGGGGR; P62,
AGAGGGAGGAGAGGGAGGAG. They represent multiple sequences in the NH3-ter-
minal half of the EBNA-1 molecule, within which the entire glycine-alanine repeat resides
(Fig. 1). All peptides have an additional COOH-terminal cysteine that is not present in
the EBNA-I sequence, but was added by us to facilitate conjugating them to protein
carriers. Purified keratin was obtained from Sigma Chemical Co. (St. Louis, MO).
Immunoblotting.
￿
We mixed FITC-labeled marker proteins with 500-700,ug of protein
extract, and this was loaded onto one 10-cm-wide slot of a 7.5% acrylamide gel. The gel
was run and transferred to nitrocellulose by the Billings et al. (25) modification of the
Towbin et al. (45) method. The sheet was stored at -20°C until use. We cut 0.5-cm strips
from the sheet and placed them in powdered milk (PM) buffer (3% commercial powdered
milk dissolved in BBS: 10 mM borate, 150 mM NaCl, pH 8 .3) for I h. Patients' sera were
diluted 1 :20 or 1 :50 in PM and reacted with the strip for 1 h at room temperature. The
strips were then washed with BBS and reacted with a solution of 0.6 ,ug/ml (in PM) of
affinity-purified rabbit anti-human IgM (The Jackson Laboratories, Avondale, PA; A
chain-specific) for 1 h at room temperature. After washing with BBS, the strips were
reacted for an additional hour at room temperature with a detecting solution of iodinated
goat anti-rabbit IgG antibody. This solution was made by labeling commercial antibody
(Kirkegaard and Perry, Gaithersburg, MD; affinity purified) by the chloramine T method
(46). The iodinated antibody was diluted in PM and used at an isotopic concentration of
2 X 105 cpm/ml (sp act ^-1 pCi/,ug). The strips were then washed and dried, and the
bands were detected by autoradiography as previously described (25, 42).
Peptide inhibitions were done by diluting the sera 1 :50 in PM and adding peptide to a
final concentration of 500,ug/ml. This solution was incubated overnight at 4°C and then





We cut a 3.0-cm-wide segment from a nitrocellulose stripthat had a
Wi-L2 extract transferred to it. This was reacted with an IM patient's serum diluted 1 :20
in PM for 2 h at room temperature. Two strips 0.4-cm wide were then cut from each end
and these were washed and treated with rabbit anti-human IgM as described above, while
the remaining 2.2-cm strip was returned to the patient's serum. After 1 h at room
temperature the smaller strips were washed and incubated for 1 h with a 1 :400 dilution
of alkaline phosphatase-coupled affinity-purified goat anti-human IgM serum (Boeh-
ringer Mannheim Biochemicals, San Diego, CA). The bands were then detected with a
color reaction that is a modification of a histological staining method for alkaline phos-
phatase (47). The strips were placed in 5 ml of 50 mM borate buffer, pH 9.5, containing
0.1 ml of a 10 mg/ml solution of fast violet and 75 tul of Naphthol AS-BI phosphate (30
mg/ml solution dissolved in N,N-dimethylformamide). Both reagents are from Sigma
Chemical Co. A recent paper by Luka et al. (34) also used a similar procedure. After 10
min in the substrate solution, the reaction was stopped by washing with PBS and then
water.
The larger 2.2-cm strip was now removed from the serum, washed with BBS and
aligned with the smaller strips. Horizontal pieces were cut in the larger strip, which
correspond to the visible bands. These were placed in plastic conical centrifuge tubes and
1 .0 ml of 50 mM diethylamine, 150 mM NaCl, pH 11 .5, was added. The solution was
gently mixed at room temperature and the strip was withdrawn. The solution was
neutralized with 0.2 M phosphate buffer, pH 2.0, and BSA was added to a final
concentration of 200 ttg/ml. The solution is diluted 1 :1 in 2x concentrated PM and
probed with a new strip as described above.
Results
Sera ofAcute IM Patients Have IgM Antibodies to a Number ofAntigens Present in
EBV-transformed B Cells. This phenomenon is shown in Fig. 2, left, where we
have blotted the sera of nine acute IM patients on electrophoresed extracts of
CA66, an EBV-transformed B cell line. A strikingly similar spectrum of antigens
is seen with all nine sera, each of which recognizes more than a dozen bands.
The nine strongest antigens, which are most evident in Fig. 2, range in size from
55 to 120 kD. These sera were all routine samples taken from patients when
they first presented with clinical symptoms. The same bands, or a subset of them,
occur in all of the several dozen acute IM sera we have screened for IgM
antibodies. The antibodies are not present in sera of two IM patients drawn
before infection (our unpublished data). They appear shortly after the first day
of illness, reaching a peak in 2-4 wk and then gradually declining over the next
year (48).
The IgM antibody pattern seen in IM patients contrasts sharply with that seen
in normal individuals. IgM antibodies to these antigens are absent in normal
healthy adults, both viral capsid antigen (VCA)-positive and VCA-. The acute
IM patients have no IgG antibodies to any protein in an EBV-transformed B cell
extract, whereas normal individuals with past EBV infection have IgG antibodies
to a single protein, the EBNA-1 protein (Fig. 2 right) (25, 49). Together these
data suggest that the antibodies seen in the IM patients are a direct response to
the acute viral infection.
All nine of the IM sera shown in Fig. 2 react also with purified human
epidermal keratin (data not shown). This protein appears on blots as two fuzzy
bands with molecular masses of 65 and 58 kD. These bands are indistinguishable
from 65 and 58 kD bands seen in blots with the cell extracts (Figs. 2-6). The
antikeratin reaction is extremely sensitive and can detect <25 ng of protein in a1030
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FIGURE 2 .
￿
Immunoblots of sera from acute IM and normal individuals . (left) The IM sera
were diluted 1:20 and used to probe strips of an electrophoresed extract of the EBV+ CA66
cell line . The bands were developed with a rabbit anti-human IgM. Normal sera show no
bands under these conditions . (right) Sera from five normal individuals were diluted 1 :100




Acute IM serum blotted on strips of elec-
trophoresed extracts of a variety of cells. The cells used
to make the extracts were : 1, Wi-L2 (EBV+ B cells) ; 2,
MC116 (EBV+ B cells); 3, HeLa (EBV- epithelial cell
line); 4, GM2504 (EBV- fibroblasts) ; 5, B95-8 (EBV+
producer marmoset B cell ; 6, EW66 (EBV+ B cells) ; 7,
human thymocytes (EBV-) ; 8, K562 (EBV- erythroleu-
kemic) . Serum 5 (Fig. 1) was diluted 1 :20 and used in
these blots . 16 jAg of protein was loaded in each lane .
Molecular mass (kD) is shown at right .
lane of a gel. Keratin is not made in any of the cells we used and probably arises
through contamination of buffers with fragments of human skin (50) . The
amount of contamination varies with the extract (compare Fig . 2 with Fig . 3)
and produces the only variation in the banding pattern .RHODES ET AL .
￿
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FIGURE 4. Elution and re-
probing with antibodies from an
IM serum . Serum 5 (Fig . 1) was
used for preliminary binding to
strips of electrophoresed WI-L2
cell extracts (left- and right-most
lanes ; marked SERUM) . Antibod-
ies were eluted from bands 2, 3,
4 + 5, 6, 7, and 8 + 9 (labeled on
the vertical axis), and then used
as probes on new strips ofelectro-
phoresed WI-L2 cell extracts
identical to those from which the
eluates were made . The horizon-
tal axis is labéled by the band
from which the antibody is de-
rived . The eluted antibodies from
all but band 3 were highly cross-
reactive . Molecular mass (kD) is
shown at left .
We chose one of the sera (serum 5 in Fig . 2) as the prototype with which to
do further studies . Fig. 3 shows blots obtained when this serum was used to
probe extracts from a number of different cells . Lanes 1, 2, 5, and 6are extracts
of various EBV-infected B cell lines . The rest are from EBV- cell lines . One can
see the same pattern of bands in all extracts (except lane 4) whether the cells
contain the EBV genome or not. Thus, numerous antigens recognized by the
IgM antibodies in acute IM sera are host-encoded proteins ; they are autoantigens .
IgMAutoantibodies Are Crossreactive .
￿
Sinceautoantibodies to the same cellular
proteins are present in almost all acute IM sera, we looked for a relationship
between them . We performed a standard immunoblot on the Wi-L2 extract ;
then we cut out the various bands and eluted the antibodies from them . These
antibodies were then used to reprobe other strips from the same cellular extract .
The results are shown in Fig . 4 . The most prominent bands are labeled 1-9 and
are shown at the side in the figure . The source of the antibody probe is shown
at the bottom . Antibodies eluted from band 3 bound only to the same band 3 .
In contrast, antibodies eluted from most of the other bands reacted not only
with their own bands, but also with all others except bands I and 3 . Most of the
antigens detected are crossreactive, and all are host encoded except for band 4,1032
￿
AUTOANTIBODIES IN INFECTIOUS MONONUCLEOSIS
FIGURE 5 .
￿
Inhibition of IgM autoantibodies by synthetic peptides . The peptides are derived
from various portions of the EBNA-1 sequence (29) . Peptides F12 and F13 are NH 2-terminal
to the glycine-alanine repeat, peptide P27 is in the transition region, and the other peptides
arefrom various portions within the glycine-alanine region . Serum 5 was diluted 1 :50 and the
peptides were added to a final concentration of 500 wg/ml and incubated overnight before
blotting . Molecular mass (kD) is shown at right .
which contains the virally encoded EBNA-1 protein as well as a host antigen .
Thus there is one viral and a variety of cellular proteins that have a common or
closely related epitope.
Autoantibodies Are Inhibited by Glycine-Alanine Peptides.
￿
We have shown sepa-
rately that theglycine-alanine portion of the EBNA-1 protein is the major epitope
for IgG anti-EBNA-1 antibodies (51) . We asked if the shared epitope seen by the
IgM antibodies in IM was related to this same repeating structure . Anumber of
peptides with sequences corresponding to various portions of the EBNA-1
molecule were used as inhibitors in the immunoblotting procedure. The data
are shown in Fig. 5. These experiments were done at a higher serum dilution
than those of Fig. 4, so that only the most prominent bands of the previous
figure, corresponding to bands 2, 4 + 5, 6, and 7-9, are easily seen .
The peptides F12 and F13, which do not contain the glycine-alanine repeating
sequence (see Materials and Methods), do not significantly inhibit antibody
binding at the concentration of inhibitor used . Peptide P27 also is a weak
inhibitor . This peptide crosses thejuncture of the repeat and thus contains two
regions, one of which is composed of glycine-alanine and the other of which is
not . The remaining peptides all contain only glycine-alanine and they all inhibit





Western blot analysis of subcellular fractions. Lane
1 contains an extract from whole cells, 2 from isolated nuclei, 3
from the cytosol, and 4 is from the particulate (membrane and
organelle) fraction . The extracts were probed with IM serum 5
diluted 1 :20 . 30 wg of protein was loaded in lane 1, 20 ag was
loaded in 2 and 4, and 13 Fag in lane 3 . The mobility of molecular
mass marker proteins (kD) is indicated on the left side ofthe figure .
dark bands at 77 kD) and band 7 (strong band at 69 kD) . There is also inhibition
ofthe fuzzy keratin bands in thearea 55-65 kD, although one prominent antigen
in this region is not inhibited at all. Also note that band 1 (weak bandjust above
2) and band 3 (weak band at 82 kD) are not inhibited by any of the peptides .
The same pattern of inhibition is seen with three other sera in the series shown
in Fig. 1 . The conclusion from these experiments is that antibody binding to
most of the crossreacting antigensareinhibited by the glycine-alanine-containing
peptides and not by peptides with other sequences . Thus the crossreacting
epitope present in the autoantigens is represented in the glycine-alanine region
ofEBNA-1 .
Cellular Autoantigens Are Distributed Throughout the Cell .
￿
Wi-L2 and K562
cells are fractionated into nuclear, cytoplasmic, and particulate (membrane and
organelle) components . Fig . 6 shows a western blot of each of these fractions
along with an extract from unfractionated whole cells . Strong bands at 92 and
77 kD are found in the nuclear fraction (Fig . 6, lane 2) . Weaker bands at 82, 76,
and 72 kD are seen in the cytoplasmic fraction (Fig . 6, lane 3) . Some normal
individuals have IgG antibodies to the 82 kD protein (H . Rumpold, G. Rhodes,
and J. H . Vaughan, manuscript in preparation) . The particulate fraction has
antigens of 105, 77, 49, and 44 kD . Additional bands at 69 and 55 kD are found
in the particulate fraction while a band at 67 kDand a broad band corresponding
to a molecular mass of 55-60 kD are seen in the nuclear fraction . Some of the
signal in this region is due to contaminating epidermal keratin, but there also
seem to be normal cellular antigens in this region . The bands at 92 and 77 kD1034
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are also present in a Triton-insoluble extract of HeLa cells and these may
represent components of the cytoskeleton. It is interesting that almost all ofthe
signal seen by immunofluorescence in these sera is directed at the vimentin class
of intermediate filaments (1-5, 7). The EBNA-1 protein runs at 77 kD and is
found both in the nuclear and cytoplasmic fractions prepared by this method
(25). The weak band seen in the cytoplasmic fraction at 77 kD is the EBNA-1
protein (our unpublished data).
Crossreacting Antigens Are Not Proteolysis Fragments.
￿
We have done several
experiments to try to eliminate the possibility that proteolysis generates the series
of crossreacting antigens. The extracts are prepared by harvesting the cells,
washing them, adding protease inhibitor, and boiling them in SDS. The whole
process takes less than 10 min (see Materials and Methods). Very little, if any,
breakdown of EBNA-1 is seen with this procedure, as evidenced by the single
78-80 kD EBNA-1 band seen in these extracts with IgG anti-EBNA-1 in normal
sera. No change in the pattern is seen if the cells are left at room temperature
for 1 h before making the extract. There is also no major change after storage
of the extract either overnight at room temperature or for many months at
-20"C. The same pattern of antigens is also seen in a variety of cell lines.
Perhapsthe bestargumentagainstextensive proteolysisis the cellular distribution
of the antigens. As discussed above, the antigens are located in separate cellular
compartments, making it unlikely that the antigens are all derived from a
precursor polypeptide that contains the crossreacting epitope. All of these data,
while indirect, suggest that no major proteolysis occurs in the cells or in the
extract.
Discussion
These studies show that there is a series of at least nine and probably more
normal cellular proteins that are recognized by IgM antibodies produced during
acute and convalescent IM. By definition, these cellular proteins are specified as
autoantigens. Some or all of these antigens are present in a variety of EBV-
infected and noninfected B cell lines, in an erythroid cell line (K562), in several
T cell lines, and in human thymocytes. The antigens are also present in HeLa
cells, but only a subset of them is detectable in a human fibroblastic cell line
(GM2504). Similar antigens are also present in murine cells and a bovine cell
line (our unpublished data), although we have not made a systematic study of
species distribution. It thus appears that these antigens are widespread both in
cell lineages and among the higher vertebrates.
The human autoantibodies reactive with these antigens display extensive
crossreactivity, in that eluates from a given cellular antigen in a Western blot are
able to recognize a series of other cellular proteins. Antibody binding to all of
these proteins is inhibited by synthetic peptides having sequences from the
glycine-alanine region of EBNA. Further, rabbit antibodies made to these same
peptides are able to recognize a subset of the crossreactive antigens (our unpub-
lished data).
The amino acid sequences of the crossreacting epitopes recognized by the IM
sera apparently need not conform precisely to the glycine-alanine prototype
found in EBNA. Human epidermal keratin has no glycine-alanine sequences,RHODES ET AL .
￿
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but it does contain a glycine-rich area flanking a polyserine region
( . . . GGGYGGGFSSSSSSFGSFFGGGYGGGL . . .), which we judge to be the
most likely site for the crossreacting epitope on this molecule (52, 53). Some of
the other cellular antigens may have peptide sequences more closely related to
the viral sequence . Siebl and Wolf (33) were able to select two cellular transcripts
that hybridized to an EBV DNA fragment coding for EBNA-I . Translation of
the RNA produced proteins of 92 and 84 kD, which may be the same as our 92
and 82 kD bands. The IM sera also recognize a 62 kD protein (sometimes
obscured by the keratin bands) that hasa mobility identical toaprotein described
by Luka et al . (34) . The 62 kD antigen reacts with a monoclonal antibody made
to EBNA-1 . Sequence variability in the crossreactive epitope may indicate that
secondary structure is an important determinant of the epitope (54 and see
below) .
It is striking that all of the 42 IM patients we have tested have IgM autoanti-
bodies to most of the same cellular proteins . The amounts of these autoantibodies
vary from patient to patient, and some patients' sera may miss some of the
weaker bands . However, every patient we have tested does have antibodies to
the prominent antigens at 92, 78-82, 69, 62, and 56 kD, although the last two
or three are sometimes obscured by contaminating epidermal keratin. The
antibodies are absent in the preillness sera, but are present in the first postonset
sample of four IM patients for which we have such serial samples . They persist
at a slowly decreasing concentration for many months after the disease . Most
patients have a small but detectable amount of IgM autoantibodies a year after
the disease, and these may persist for up to 2 yr in some people .
The kinetics of appearance of antibody to EBNA-1 is highly unusual among
the anti-EBV antibodies . IgG antibodies to all other EBV antigens are present
early in the symptomatic phase of the disease (21, 22), which is some weeks after
the initial infection . In contrast, IgG anti-EBNA-1 antibodies, as measured by
the classical anticomplement immunofluorescence (ACIF) assay (44), usually
become detectable only months after infection . This fact is exploited in the
diagnosis of primary acute EBV infection (21, 22, 48) . We have previously
reported (26, 42) that an ELISA assay for anti-EBNA-1 antibodies, using as
antigen synthetic peptides from theglycine-alanine region ofEBNA, detects IgM
anti-EBNA-1 peptide antibodies during the early symptomatic stage of the
disease, but IgG anti-EBNA-1 peptide antibodies (as with the ACIF measurement
of anti-EBNA-1) usually do not appear for several months .
In contrast to IgM, IgG antibodies to EBNA-1 are very specific for EBNA-1 ;
normally they do not recognize the cellular proteins seenby the IgM anti-EBNA-
1 antibodies (25, 49). Both IgG and IgM anti-EBNA-1 antibodies are, neverthe-
less, directed predominantly to the same glycine-alanine region in EBNA-1 .
Perhaps the early IgM autoantibodies, produced as part of a T cell-independent
anti-EBNA-1 glycine-alanine response, switch to the IgG isotype only with
difficulty . This switch must await clonal expansion of rare anti-EBNA-1 antibod-
ies that do not recognize the crossreactive self antigens . The production of IgG
anti-EBNA-1 antibodies thus wouldbe the result ofa lengthy andtime-consuming
process and would ordinarily result in antibodies specific for EBNA-1 and not
crossreactive with the similar cellular antigens .1036
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EBNA-1 antibody synthesis provides a system to study the mechanism of
immune tolerance during a normal humanimmune response. Hereaviral protein
that shares epitopes with a number of human components is introduced well
after the maturationofthe immunesystem. The early IgM antibodies are broadly
crossreactive, while the IgG antibodies react exclusively with the viral protein.
Despite the increased specificity of the IgG isotype, both the IgG and IgM
antibodies are directed at the same glycine-alanine epitopes (51). These results
can be used to exclude several proposed mechanisms of tolerance (reviewed in
55). We see the same autoantibodies occurring in every IM patient we have
examined, so tolerance cannot be due to the absence of B cell precursors. The
increase in crossreacting antibodies early in the disease also makes it unlikely
that direct B cell blocking occurs. The most reasonable assumption is that
tolerance involves T cells, perhaps during isotype switching. Further characteri-
zation of the system should allow more definitive conclusions to be drawn.
Although our studies do not demonstrate the means by which these glycine-
alanine-crossreactive IgM autoantibodies arise, it seems reasonable to regard
them as a component of the anti-EBNA-1 response. The kinetics of their
appearance and disappearance is consistent with this (26, 42). The alternative
explanation that the autoantibodies are simply the result of immunization with
cellular antigens spilled from damaged or dying cells may conceivably account
for some autoantibodies. However, we do not see anti-glycine-alanine antibodies
in the sera ofburn or trauma patients (none seen among 20 patients examined),
and they are present in <5% (3 of64) ofpatients with otheracute viral infections
(our unpublished data).
Polyclonal B cell activation in its simplest form is also unlikely by itself to
account fortheautoantibodies we describe here, because ofits inherently random
nature. If this mechanism were responsible forproducing the autoantibodies we
describe, one would have expected only a portion of the patients to produce
autoantibodies to any specific protein, and one would not expect the autoanti-
bodies to be crossreactive. A possibility not excluded by these data is polyclonal
activation ofa germline-encoded antibody that possesses broad crossreactivity to
the glycine-alanine region. Because theseantibodies requirefewifany mutations,
they should have high precursor frequencies and should be very similar in all
individuals. Experiments to test these ideas are presently in progress.
The autoantibodies we describe also fulfill the expectations of the epitope
homology (mimicry) model. They appear in all patients who produce antibodies
to the viral protein during acute infection, they form a crossreactive set of
proteins, and they are inhibited by a common sequence derived from the viral
protein. These data, taken together, form a strong case for molecular mimicry
in generating autoantibody production during IM, and they offer the first
demonstration of the specific structure within a molecule responsible for the
homology.
Summary
Viruses have been postulated to be involved in the induction ofautoantibodies
by: (a) autoimmunization with tissue proteins released by virally induced tissue
damage; (b) immunization with virally encoded antigens bearing molecularsimilarities to normal tissue proteins; or (c) nonspecific (polyclonal) B cell stimu-
lation by the infection . Infectious mononucleosis (IM) is an experiment of nature
that provides the opportunity for examining these possibilities. We show here
that IgM antibodiesproduced in this disease react with at least nine normal tissue
proteins, in addition to the virally encoded Epstein-Barr nuclear antigen (EBNA-
1) . The antibodies are generated to configurations in the glycine-alanine repeat
region of EBNA-1 and are crossreactive with the normal tissue proteins through
similar configurations, as demonstrated by the effectiveness ofa synthetic glycine-
alanine peptide in inhibiting the reactions . The antibodies are absent in preillness
sera and gradually disappear over a period of months after illness, being replaced
by IgG anti-EBNA-1 antibodies that do not crossreact with the normal tissue
proteins but that are still inhibited by the glycine-alanine peptide . These findings
are most easily explained by either a molecular mimicry model of IgM autoanti-
body production or by the polyclonal activation of a germline gene for a
crossreactive antibody . It also indicates a selection of highly specific, non-
crossreactive anti-EBNA-1 antibodies during IgM to IgG isotype switching .
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